The prognostic significance of HER2 positivity for advanced gastric cancer patients undergoing first-line modified FOLFOX-6 regimen. 2012

Jin Won Kim, and Seock-Ah Im, and Miso Kim, and Yongjun Cha, and Kyung-Hun Lee, and Bhumsuk Keam, and Min A Kim, and Sae-Won Han, and Do-Youn Oh, and Tae-You Kim, and Woo Ho Kim, and Yung-Jue Bang
Department of Internal Medicine, Seoul National University College of Medicine, Seoul National University, Seoul, Korea.

OBJECTIVE We aimed to clarify the prognostic significance of HER2 positivity in advanced gastric cancer. METHODS The cohort included patients with initially metastatic or recurrent gastric cancer treated with first-line modified FOLFOX-6. The HER2 status was analyzed according to modified scoring criteria specific for gastric cancer. RESULTS HER2 positivity was shown in 10 out of 114 patients (9.0%). The median time-to-progression (TTP) (4.3 months, 95% confidence interval (CI)=3.6-4.9) and the overall survival (OS) (7.5 months, 95% CI=6.1-8.8) of patients with HER2-positive gastric cancer tended to be shorter than the median TTP (5.9 months, 95% CI=4.5-7.2) and OS (10.8 months, 95% CI=9.2-12.3) of those with HER2-negative gastric cancer (TTP, p=0.177; OS, p=0.068). Particularly in the subgroup of patients without diffuse-type histology, HER2-positive gastric cancer had a worse TTP than those with HER2-negative gastric cancer (p=0.024). In multivariate analysis of this subgroup, HER2 positivity and ECOG performance status of 2 were associated with shorter TTP (hazard ratio (HR)=2.926, p=0.014; HR=2.489, p=0.035, respectively). CONCLUSIONS HER2-positive gastric cancer seems to confer poorer prognosis, particularly in patients without diffuse-type tumor, treated with modified FOLFOX-6.

UI MeSH Term Description Entries
D007150 Immunohistochemistry Histochemical localization of immunoreactive substances using labeled antibodies as reagents. Immunocytochemistry,Immunogold Techniques,Immunogold-Silver Techniques,Immunohistocytochemistry,Immunolabeling Techniques,Immunogold Technics,Immunogold-Silver Technics,Immunolabeling Technics,Immunogold Silver Technics,Immunogold Silver Techniques,Immunogold Technic,Immunogold Technique,Immunogold-Silver Technic,Immunogold-Silver Technique,Immunolabeling Technic,Immunolabeling Technique,Technic, Immunogold,Technic, Immunogold-Silver,Technic, Immunolabeling,Technics, Immunogold,Technics, Immunogold-Silver,Technics, Immunolabeling,Technique, Immunogold,Technique, Immunogold-Silver,Technique, Immunolabeling,Techniques, Immunogold,Techniques, Immunogold-Silver,Techniques, Immunolabeling
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009362 Neoplasm Metastasis The transfer of a neoplasm from one organ or part of the body to another remote from the primary site. Metastase,Metastasis,Metastases, Neoplasm,Metastasis, Neoplasm,Neoplasm Metastases,Metastases
D009944 Organoplatinum Compounds Organic compounds which contain platinum as an integral part of the molecule. Compounds, Organoplatinum
D011379 Prognosis A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations. Prognostic Factor,Prognostic Factors,Factor, Prognostic,Factors, Prognostic,Prognoses
D012008 Recurrence The return of a sign, symptom, or disease after a remission. Recrudescence,Relapse,Recrudescences,Recurrences,Relapses
D002955 Leucovorin The active metabolite of FOLIC ACID. Leucovorin is used principally as an antidote to FOLIC ACID ANTAGONISTS. Calcium Leucovorin,Citrovorum Factor,Folinic Acid,N(5)-Formyltetrahydrofolate,5-Formyltetrahydrofolate,5-Formyltetrahydropteroylglutamate,Calcium Folinate,Folinic Acid-SF,Leucovorin, (D)-Isomer,Leucovorin, (DL)-Isomer,Leucovorin, (R)-Isomer,Leucovorin, Calcium (1:1) Salt,Leucovorin, Calcium (1:1) Salt, (DL)-Isomer,Leucovorin, Calcium (1:1) Salt, Pentahydrate,Leucovorin, Monosodium Salt,Leukovorin,Leukovorum,Wellcovorin,5 Formyltetrahydrofolate,5 Formyltetrahydropteroylglutamate,Acid, Folinic,Factor, Citrovorum,Folinate, Calcium,Folinic Acid SF,Leucovorin, Calcium,Monosodium Salt Leucovorin
D005260 Female Females
D005472 Fluorouracil A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid. 5-FU,5-FU Lederle,5-FU Medac,5-Fluorouracil,5-Fluorouracil-Biosyn,5-HU Hexal,5FU,Adrucil,Carac,Efudex,Efudix,Fluoro-Uracile ICN,Fluoroplex,Fluorouracil Mononitrate,Fluorouracil Monopotassium Salt,Fluorouracil Monosodium Salt,Fluorouracil Potassium Salt,Fluorouracil-GRY,Fluorouracile Dakota,Fluorouracilo Ferrer Far,Fluoruracil,Fluracedyl,Flurodex,Haemato-FU,Neofluor,Onkofluor,Ribofluor,5 FU Lederle,5 FU Medac,5 Fluorouracil,5 Fluorouracil Biosyn,5 HU Hexal,Dakota, Fluorouracile,Fluoro Uracile ICN,Fluorouracil GRY,Haemato FU

Related Publications

Jin Won Kim, and Seock-Ah Im, and Miso Kim, and Yongjun Cha, and Kyung-Hun Lee, and Bhumsuk Keam, and Min A Kim, and Sae-Won Han, and Do-Youn Oh, and Tae-You Kim, and Woo Ho Kim, and Yung-Jue Bang
January 2011, Hepato-gastroenterology,
Jin Won Kim, and Seock-Ah Im, and Miso Kim, and Yongjun Cha, and Kyung-Hun Lee, and Bhumsuk Keam, and Min A Kim, and Sae-Won Han, and Do-Youn Oh, and Tae-You Kim, and Woo Ho Kim, and Yung-Jue Bang
February 2012, Oncology letters,
Jin Won Kim, and Seock-Ah Im, and Miso Kim, and Yongjun Cha, and Kyung-Hun Lee, and Bhumsuk Keam, and Min A Kim, and Sae-Won Han, and Do-Youn Oh, and Tae-You Kim, and Woo Ho Kim, and Yung-Jue Bang
March 2010, Cancer research and treatment,
Jin Won Kim, and Seock-Ah Im, and Miso Kim, and Yongjun Cha, and Kyung-Hun Lee, and Bhumsuk Keam, and Min A Kim, and Sae-Won Han, and Do-Youn Oh, and Tae-You Kim, and Woo Ho Kim, and Yung-Jue Bang
April 2009, Anti-cancer drugs,
Jin Won Kim, and Seock-Ah Im, and Miso Kim, and Yongjun Cha, and Kyung-Hun Lee, and Bhumsuk Keam, and Min A Kim, and Sae-Won Han, and Do-Youn Oh, and Tae-You Kim, and Woo Ho Kim, and Yung-Jue Bang
June 2008, American journal of clinical oncology,
Jin Won Kim, and Seock-Ah Im, and Miso Kim, and Yongjun Cha, and Kyung-Hun Lee, and Bhumsuk Keam, and Min A Kim, and Sae-Won Han, and Do-Youn Oh, and Tae-You Kim, and Woo Ho Kim, and Yung-Jue Bang
April 2008, British journal of cancer,
Jin Won Kim, and Seock-Ah Im, and Miso Kim, and Yongjun Cha, and Kyung-Hun Lee, and Bhumsuk Keam, and Min A Kim, and Sae-Won Han, and Do-Youn Oh, and Tae-You Kim, and Woo Ho Kim, and Yung-Jue Bang
September 2015, Molecular and clinical oncology,
Jin Won Kim, and Seock-Ah Im, and Miso Kim, and Yongjun Cha, and Kyung-Hun Lee, and Bhumsuk Keam, and Min A Kim, and Sae-Won Han, and Do-Youn Oh, and Tae-You Kim, and Woo Ho Kim, and Yung-Jue Bang
March 2009, Zhonghua zhong liu za zhi [Chinese journal of oncology],
Jin Won Kim, and Seock-Ah Im, and Miso Kim, and Yongjun Cha, and Kyung-Hun Lee, and Bhumsuk Keam, and Min A Kim, and Sae-Won Han, and Do-Youn Oh, and Tae-You Kim, and Woo Ho Kim, and Yung-Jue Bang
August 2020, Asian Pacific journal of cancer prevention : APJCP,
Jin Won Kim, and Seock-Ah Im, and Miso Kim, and Yongjun Cha, and Kyung-Hun Lee, and Bhumsuk Keam, and Min A Kim, and Sae-Won Han, and Do-Youn Oh, and Tae-You Kim, and Woo Ho Kim, and Yung-Jue Bang
September 2007, Gan to kagaku ryoho. Cancer & chemotherapy,
Copied contents to your clipboard!